Journal ArticleDOI
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
Ludwig Kappos,David W. Bates,Gilles Edan,Mefkure Eraksoy,Antonio Garcia-Merino,Nikolaos Grigoriadis,Hans Peter Hartung,Eva Havrdova,Jan Hillert,Reinhard Hohlfeld,Marcelo Kremenchutzky,Olivier Lyon-Caen,Ariel Miller,Carlo Pozzilli,Mads Ravnborg,Takahiko Saida,Christian Sindic,Karl Vass,David B. Clifford,Stephen L. Hauser,Eugene O. Major,Paul O'Connor,Howard L. Weiner,Michel Clanet,Ralf Gold,Hans H. Hirsch,Ernst W. Radü,Per Soelberg Sørensen,John King +28 more
TLDR
This Review revisits and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.Abstract:
Natalizumab, a highly specific α4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.read more
Citations
More filters
Journal ArticleDOI
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L. Hauser,Amit Bar-Or,Giancarlo Comi,Gavin Giovannoni,Hans Peter Hartung,Bernhard Hemmer,Fred D. Lublin,Xavier Montalban,Kottil Rammohan,Krzysztof Selmaj,A. Traboulsee,Jerry S. Wolinsky,Douglas L. Arnold,Gaelle Klingelschmitt,Donna Masterman,Paulo Fontoura,Shibeshih Belachew,Peter Chin,N. Mairon,Hideki Garren,Ludwig Kappos +20 more
TL;DR: Among patients with relapsing multiple sclerosis, ocrelizumab was associated with lower rates of disease activity and progression than interferon beta‐1a over a period of 96 weeks.
Journal ArticleDOI
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
TL;DR: Experimental encephalomyelitis (EAE) is the most commonly used experimental model for the human inflammatory demyelinating disease, multiple sclerosis (MS), which is a complex condition in which the interaction between a variety of immunopathological and neuropathological mechanisms leads to an approximation of the key pathological features of MS as discussed by the authors.
Journal ArticleDOI
The safety and side effects of monoclonal antibodies
TL;DR: Some of the adverse effects encountered with mAb therapies are reviewed, and advances in preclinical testing and antibody technology aimed at minimizing the risk of these events are discussed.
Journal ArticleDOI
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
Kenneth R. Carson,Andrew M. Evens,Elizabeth A. Richey,Thomas M. Habermann,Daniele Focosi,John F. Seymour,Jacob P. Laubach,Susie D. Bawn,Leo I. Gordon,Jane N. Winter,Richard R. Furman,Julie M. Vose,Andrew D. Zelenetz,Andrew D. Zelenetz,Ronac Mamtani,Dennis W. Raisch,Gary W. Dorshimer,Steven T. Rosen,Kenji Muro,Numa R. Gottardi-Littell,Robert L. Talley,Oliver Sartor,David Green,Eugene O. Major,Charles L. Bennett,Charles L. Bennett +25 more
TL;DR: Overall, 52 patients with lymphoproliferative disorders, 2 patients with systemic lupus erythematosus, 1 patient with rheumatoid arthritis,1 patient with an idiopathic autoimmune pancytopenia, and 1 patientwith immune thrombocytopenIA developed PML after treatment with rituximab and other agents from 1997 to 2008.
Journal ArticleDOI
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos,David Kb Li,Peter A. Calabresi,Paul O'Connor,Amit Bar-Or,Frederik Barkhof,Ming Yin,David Leppert,Robert Glanzman,Jeroen Tinbergen,Stephen L. Hauser +10 more
TL;DR: The similarly pronounced effects of B-cell depletion with both ocrelizumab doses on MRI and relapse-related outcomes support a role for B-cells in disease pathogenesis and warrant further assessment in large, long-term trials.
References
More filters
Journal ArticleDOI
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
Chris H. Polman,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,David Miller,J. Theodore Phillips,Fred D. Lublin,Gavin Giovannoni,A Wajgt,Martin Toal,F Lynn,Michael Panzara,Alfred Sandrock +12 more
TL;DR: Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.
Journal ArticleDOI
J. Virol. Methods: Corrigendum to “Detection of stylet-borne and circulative potato viruses in aphids by duplex reverse transcription polymerase chain reaction” [59 (1996) 189]
Journal ArticleDOI
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
Lawrence Jacobs,Diane Cookfair,Richard A. Rudick,Robert M. Herndon,John R. Richert,Andres M. Salazar,J. S. Fischer,Donald E. Goodkin,Carl V. Granger,Jack H. Simon,John J. Alam,David M. Bartoszak,Dennis Bourdette,Jonathan Braiman,Carol M. Brownscheidle,Michael E. Coats,Stanley Cohan,David S. Dougherty,R. P. Kinkel,Michele Mass,Frederick Munschauer,Roger L. Priore,Patrick M. Pullicino,Barbara J. Scherokman,Bianca Weinstock-Guttman,Ruth H. Whitham +25 more
TL;DR: Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.